Abstract
S-1108 was administered to 8 patients with respiratory tract infection and clinical efficacy and safety were evaluated.
1) Eight patients with respiratory tract infections (tonsillitis 1, pharyngolaryngitis 3, bronchitis 2, pneumonia 2) were treated with 300-450mg daily of oral S-1108 for 7 to 8 days. The clinical effect was evaluated as good in six patients, and fair in two.
2) No adverse reactions were observed in any of the patients.
